What You Ought to Know:
– WeightWatchers, the worldwide chief in science-backed weight administration, introduced a growth of its collaboration with Novo Nordisk that will enhance entry to genuine, FDA-approved Wegovy® (semaglutide) injection by way of WeightWatchers Clinic.
– The collaboration goals to simplify the prescription course of, improve affordability, and discover real-world analysis initiatives to enhance long-term outcomes for people managing their weight.
Streamlined Entry and Affordability for Members
As a part of the expanded collaboration, WeightWatchers Clinic members will profit from a simplified prescription course of by way of NovoCare® Pharmacy. CenterWell Pharmacy®, a seven-time MMIT Specialty Pharmacy Affected person Selection Award winner, will function the allotting pharmacy for the NovoCare® program. It will facilitate direct success and residential supply of Wegovy® prescriptions for WeightWatchers Clinic members.
Along with simplified supply, WeightWatchers will improve the member expertise by offering built-in account entry, bundled pricing alternatives, stock visibility, and cargo monitoring.
To additional increase entry, Novo Nordisk is providing a limited-time financial savings provide. Beginning July 1, 2025, eligible cash-pay members of WeightWatchers Clinic can entry Wegovy® at a decreased worth of $299 till July 31, 2025. This vital saving is aimed toward broadening entry to clinically validated, FDA-regulated therapy choices.
Actual-World Analysis and Scientific Affect
WeightWatchers and Novo Nordisk may also discover alternatives for additional collaboration on real-world analysis initiatives and techniques to enhance long-term outcomes. The goal is to guage the potential affect of mixing Wegovy®, essentially the most broadly used GLP-1 treatment globally, with WeightWatchers’ diet and behavioral assist program, to reveal the scientific and financial worth of this built-in care mannequin.
Wegovy®, first permitted in 2021, is the one FDA-approved semaglutide therapy for weight reduction. It remodeled weight problems therapy as the primary weekly GLP-1 for power weight administration and at present helps almost 1.5 million sufferers within the U.S.. In 2024, the FDA expanded Wegovy®’s label to incorporate a sign for lowering the chance of main cardiovascular occasions in adults with identified coronary heart illness and both weight problems or chubby.
Preliminary real-world proof is promising: a examine of three,260 WeightWatchers Clinic members prescribed a GLP-1 confirmed members misplaced a mean of 21% of their physique weight at 12 months, indicating that combining a GLP-1 with WeightWatchers’ holistic assist mannequin can ship superior, sustainable outcomes.
Scott Honken, Chief Business Officer at WeightWatchers, acknowledged, “By deepening our collaboration with Novo Nordisk, we’re serving to extra individuals entry the FDA-approved therapy they deserve, delivered inside a holistic scientific mannequin confirmed to assist actual, sustainable and improved well being outcomes”. He emphasised that WeightWatchers “stays the trusted chief, bringing collectively entry to protected, FDA-approved treatment and best-in-class way of life assist, setting the bar for the gold normal of accountable weight administration”.
